| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3684 |
| Trial ID | NCT06154252 |
| Disease | Idiopathic Inflammatory Myopathy | Dermatomyositis | Anti-Synthetase Syndrome | Immune-Mediated Necrotizing Myopathy |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CABA-201 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy |
| Year | 2023 |
| Country | United States |
| Company sponsor | Cabaletta Bio |
| Other ID(s) | CAB-201-002 |
| Cohort 1 | |||||||||||
|
|||||||||||